DC 9476
Alternative Names: DC-9476Latest Information Update: 23 Aug 2024
At a glance
- Originator DeepCure
- Class Antirheumatics; Small molecules
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 19 Aug 2024 DeepCure enters into a collaboration agreement with the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) to investigate DC 9476 for Rheumatoid arthritis
- 19 Aug 2024 Preclinical trials in Rheumatoid arthritis in USA (unspecified route), prior to August 2024
- 08 Aug 2024 Pharmacodynamics and adverse events data from a preclinical trial in Rheumatoid arthritis released by DeepCure